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Background: Adverse events and impairments associated with cancer and its treatments causes 
worse outcomes. Increased incidence of renal diseases among cancer patients is of particular 
concern. Objective: To determine the risk factors for renal disease in cancer patients and 
compare healthcare costs, utilization and health-related quality of life (HRQoL) of cancer 
patients with a renal disease and cancer patients without renal diseases. Methods: Medical 
Expenditure Panel Survey files from 2009 – 2018 for cancer patients was used for this study.  
Multiple logistic regression, generalized linear model, Poisson regression and multiple linear 
regression for analyses after adjusting for demographic, socioeconomic and clinical factors. 
Healthcare costs and utilization were determined in propensity score matched cohorts. Results:  
Renal disease was present in 16% of cancer patients in United States. Cancer patients with renal 
disease had higher adjusted mean healthcare expenditure from all sources of payments for 
office-based visits to a provider ($7,881 vs $5.683), prescription medicines ($11,068 vs $6,764), 
total medical cost ($37,283 vs $22,403) as compared to cancer patients without renal diseases. 
Cancer patients with renal disease had higher median prescriptions filled (89 vs 57) and office-
based visits to a physician (31 vs 21), higher PCS scores (40.52 vs 45.25) and MCS scores (50.31 
vs 51.37). Conclusion: Cancer patients with renal disease had higher healthcare expenditure, 
resource utilization and worse health-related quality of life than cancer patients without renal 
disease, emphasizing the need of targeted care towards cancer patients with renal disease to 
have better health outcomes.
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Chapter 1: BACKGROUND 
Cancer is a major public health problem worldwide and is the second leading cause of 
death in the United States.1 In 2018, 21% of the deaths recorded in the United States were 
attributed to cancer.2 In 2021, it is estimated that prostate, lung and colorectal cancers will 
account for 46% of all incident cases in men, with prostate cancer alone accounting for 26% of 
diagnoses. For women, breast cancer, lung, and colorectal cancers will account for 50% of all new 
diagnoses, with breast cancer alone accounting for 30% of female cancers.2 Cancer survivors are 
projected to increase from 16.9 million people in 2019, to 22.2 million people in 2030.3 The 5-
year survival rates from 2010 to 2016 was highest for prostate cancer (98%), melanoma of the 
skin (93%), and female breast cancer (90%) and lowest for cancers of the pancreas (10%), liver 
(20%), esophagus (20%), and lung (21%).4 The 5-year survival of cancer patients has increased 
from 35% in 1950-1954 to 67.4% in 2010-2016.4 The increase in survival rate can be attributed to 
factors like early detection practices, advances in curative therapy, increased life expectancy and 
growth of an aging population.2 The consequences of increased survival include increasing 
complications associated with the disease process.5  
The economic burden of adverse events and complications in cancer patients is 
substantial.6-10 The Agency for Healthcare Research and Quality’s (AHRQ) Medical Expenditure 
Panel Survey estimated that for 2017, the direct medical costs for cancer, including all health care 
expenditures, were $105.5 billion, of which 52% was spent on hospital outpatient or office-based 
provider visits, 23.2% on inpatient hospital stays, and 19.6% on prescription medications.11 
Financial hardship can lead to lower quality of life, increased pain and greater symptom 
burden.12-13  Due to treatment or disease burden, cancer patients have lower quality of life due 
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to physical symptoms like fatigue, pain, and nausea and vomiting, psychological symptoms like 
anxiety and depression, and limitations and difficulty in performing daily activities.14 
Cancer treatments include systemic therapies such as chemotherapy, targeted therapy 
and immunotherapies. These therapies are used alone or in combination with localized therapies 
such as surgeries, radiation, heat or chemical ablation. Cancer therapies are effective but long-
term cancer treatments can cause adverse effects and complications like anemia, nausea, 
vomiting, neurotoxicity, nephrotoxicity.15,16 Management of adverse events and impairments 
associated with cancer and its treatment is important because they influence adherence to 
cancer therapies and quality of life.17 Increased incidence of kidney diseases among patients with 
cancer is of particular concern because a decrease in renal function often requires dose 
adjustment which may include decreasing the dose or stopping the use of certain 
chemotherapeutic agents. This may delay or reduce the overall effectiveness of the cancer 
treatment. Several mechanisms may underlie the high rate of renal disease in cancer patients 
including drugs required to treat the malignancy and the nature of underlying disease causes 
cancer patients to more likely to have renal diseases.18-22,  
1.1 DRUG-INDUCED NEPHROPATHY 
Kidneys are the main site of drug elimination for metabolites of systemic therapies. 
Hence, they are exposed to high concentrations of metabolites of systemic therapies. Systemic 
therapeutic agents such as ifosamide, tyrosine kinase inhibitors, premetrexed, cisplatin have 
been associated with tubular toxicity.23 Nephrotoxicity of cisplatin, gemcitabine, mitomycin and 
bevacizumab manifests as a glomerular disease in cancer patients as thrombotic 
micoangiopathy.24-26 Immune checkpoint inhibitors like pembrolizumab and nivolumab causes 
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acute injury.83 Electrolyte abnormalities are caused by cetuximab, panitumumab, imatinib27-30 
supportive care drugs like pain medications, antibiotics, antihistamines, antivirals, antacids, 
bisphosphonates have been established to have some degree of nephrotoxicity.18 
Chemotherapeutic drugs also cause nausea, vomiting, diarrhea and poor oral intake. These 
adverse events cause volume depletion.19  
1.2 LOCALIZED THERAPY ASSOCIATED KIDNEY DISEASE 
Radiotherapy is often used in adjuvant to systemic therapies. Radiation has been 
associated with renal injury. However due to long latency for radiotherapy induced kidney injury 
and high prevalence of confounding factors, the magnitude of the effect of radiotherapy is 
unclear.31 Obstruction of the urinary tract by malignancy can occur due in patients with 
genitourinary cancer.  Renal cell carcinoma is a common genitourinary malignancy. Patients are 
commonly recommended for a partial and radical nephrectomy. Evidence suggests that these 
surgeries increase the risk of AKI in short term and chronic kidney disease (CKD) both in long 
term.32 
1.3 INDIRECT CAUSES OF RENAL DISEASE 
Antitumor activities of novel target therapies increase the risk of patients experiencing 
tumor lysis syndrome. Tumor lysis syndrome leads to formation of uric acid crystals which causes 
renal damage.20 Apart from this, tumor lysis syndrome also causes an imbalance of acid-base and 
electrolytes in the bloodstream which affects kidneys. Patients with cancer are at a higher risk 
for infections due to alterations in innate and adaptive immunity from the malignancy and 
aggressive cancer therapies. 2.3 million hospital bed days and $3 billion were attributed to 
infections in cancer patients and it is estimated to increase to 3.4 million hospital bed days and 
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$4.5 million expenditure.33 Cancer patients are 10 times more likely to develop sepsis compared 
to the general population.34 20% of ICU admissions are cancer patients with sepsis being the 
leading reason of admission. These complications increase the length of stay and overall costs. 
Evidence suggests that AKI occurs in 19% of patients with moderate sepsis, 23% with severe 
sepsis and 51% with septic shock.35–37 Previous literature has also suggested a link between 
cardiovascular and renal disease where both have common risk factors. Patients with CKD have 
a high prevalence of hypertension.21 Hepatorenal syndrome is another risk factor which causes 
pre-renal AKI. 22   
Common renal diseases in cancer patients include acute kidney injury and chronic renal 
disease. Membranous Nephropathy is the most common type of renal disease associated with 
solid tumors.38 IgA nephropathy, membranoproliferative glomerulonephritis and extra capillary 
glomerulonephritis have also been reported, in case studies although less commonly than other 
renal diseases mentioned previously.  
With newer therapies which improve the overall survival of cancer patients, long-term 
management of patients who develop renal diseases from their cancer treatment is essential. 
Decrease in renal function often requires a dose adjustment which may include decreasing the 
dose or stopping the use of certain chemotherapeutic agents which may delay or reduce the 
overall effectiveness of the cancer treatment. This emphasizes the need for early detection and 
intervention to alleviate the cause of renal disease. Studies in non-cancer patients with renal 
diseases have shown longer hospitalization, increased hospital costs and lower quality of life.39 
Cancer and CKD are the costliest conditions for Part B Medicare beneficiaries and evidence 
suggests that presence of renal disease in cancer patients increases length of stay, and 
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mortality.40-42 We hypothesize in our study that cancer patients with renal disease would also 
have higher healthcare utilization, expenditure and lower quality of life than cancer patients who 




Chapter 2: LITERATURE REVIEW  
A literature review was conducted to identify research articles which assesses the 
economic burden and quality of life associated with renal disease in cancer patients. The review 
and search were carried out in May 2020 in PubMed and CINAHL with a combination of keywords 
and MeSH terms. The search query used was a combination of: “Kidney Diseases” [Mesh], 
“Nephrotoxic*”, “Kidney toxic*”, “Renal toxic*”, "Observational Studies as Topic"[Mesh] “Cohort 
Studies” [Mesh], “Observational Study” [Publication Type], “Neoplasms” [Mesh], “Cancer*”, 
“malignan*”, “carcinoma*”, “metastat*” and “tumour*”. Titles and abstracts were screened. 
The following inclusion and exclusion criteria were applied: 
Inclusion Criteria: 
1) Studies conducted in cancer patients over 18 years of age 
2) Studies with specific renal outcomes 
Exclusion Criteria: 
1) Case reports and reviews 
2) Studies where renal disease is a post-surgery complication 
3) Studies which built and validated predictive models 
4) Studies which tested interventions to treat renal diseases 
5) Studies not conducted in United States 
1,148 articles were retrieved from the database and their titles and abstracts were read and 
1,131 articles were excluded based on the exclusion criteria. The full-texts of remaining articles 
were accessed and read for including only eligible articles in the review. After reading the full 
texts, 7 articles were excluded based on the exclusion criteria and 10 articles were selected for 
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the final review.43-52 These 10 articles are summarized in Table 1 which includes 7 articles with 
the objective of estimating risk factors associated with renal diseases and 3 articles which aim at 
estimating healthcare utilization and expenditure associated with renal diseases. 
 


















Articles selected for final 
review 
(N = 10) 
Full text articles assessed for 
eligibility (N = 17) 
Titles and abstracts screened 
(N = 1,148) 
Studies identified through 
database searching (N = 1,148) 
Articles excluded (N = 1,131) 
• Cases and Reviews (N = 645) 
• Non-Renal Outcomes (N = 289) 
• Clinical Trials (N = 184) 
• Studies not done in the US (N = 13)  
  Articles excluded (N = 7) 
• Cases and Reviews (N = 3) 
• Non-Renal Outcomes (N = 2) 
































Table 1: Literature from PUBMED and CINAHL summarized  
SR. NO AUTHORS OBJECTIVE SAMPLE POPULATION RESULTS 
STUDIES ASSESSING RISK AND PREVALENCE 
1 Li et al. 
43 




acute kidney injury 
(AKI) 
Elderly Medicare 
enrollees with newly 
diagnosed early- stage 
breast cancer 
Chemotherapy treated 
patients are 2.73 times 
more likely to have AKI 
than untreated patients. 
Incidence of AKI: Taxane > 





To estimate the 
incidence of AKI and to 
evaluate the risk factors 
for AKI 
Patients with acute 
myelogenous leukemia  





no AKI – 64%; Risk – 15%; 
Injury – 10%; Failure – 11% 
3 Arellano  
et al.45 
To estimate the 




Patients with bone 
metastases from 
solid tumors 
5-year prevalence of RI - 
43%. 46% CKD patients 
received intravenous 
bisphosphonates in the 12 
months following their 
confirming eGFR. 13% of 
these patients received at 
least one other 




To assess kidney 
function outcomes 
Patients undergoing 
surgery for renal cortical 
tumor in cancer center 
Patients who underwent 
radical nephrectomy had a 
higher risk (3.82 times) of 
CKD than those who 
underwent partial 
nephrectomy 
5 Qian et 
al. 47 
To estimate the 




Patients with multiple 
myeloma 
6-month prevalence after 
multiple myeloma diagnosis:  
RI – 47%, CKD – 27% 
12 months after multiple 
myeloma diagnosis:  







12% of the admitted patients 
had AKI; Risk – 68%, Injury – 
21%, Failure – 11%. Length 
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al.48 clinical correlates, 
and outcomes of AKI 
of stay (100%), cost (106%) 
and odds of mortality (4.7-
fold) was significantly greater 
7 Lahoti 
et al.49 
To estimate the 
incidence, outcomes, 




AKI – 12.6%; risk – 6%; 
injury – 3%; failure – 4%; 
Each percent increase in 
serum creatinine was 
associated with a 0.16% 
increase in cost 
STUDIES ASSESSING HEALTHCARE UTILIZATION AND EXPENDITURE 





use and costs 
associated 
with RI 
Patients with bone 
metastases from 
solid tumors 
Outpatient services (38.4 vs 
26.7); Emergency dept visits 
(6.8 vs 3.9); Hospital 
admission ($72,557 vs 
$27,858); Total healthcare 
cost ($142,267 vs $88,839) 
9 Bhowmi 









No. of patients with an 
admission (57.1% vs 
32.1%); Frequency of 
prescription fills (90.2 vs 
66.9); Office visits (35.7 vs 
30.1); Frequency of 
Laboratory services (96.9 
vs 66.4); Total healthcare 
cost ($106,634 vs 
$71,880); 
10.  Candrill
i et al. 
52 
To compare 
inpatient length of 





ARF and RD - $44,619; ARF 
and no RD - $25,638; no 
ARF and no RD - $13,947 
ARF – Acute Renal Failure; RD – Renal Dialysis; AKI – Acute Kidney Injury; CKD – Chronic Kidney 
Disease; RI – Renal Impairment; eGFR – estimated Glomerular Filtration Rate; 
 
STUDIES ASSESSING RISK AND PREVALENCE 
A study by Li et al. examined the association between adjuvant chemotherapy and acute 
kidney injury in elderly Medicare enrollees who were newly diagnosed with early-stage breast 
cancer.43 They used the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare 
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database and found that after adjusting for baseline characteristics, adjuvant chemotherapy 
increased the risk of AKI by almost 3 times (HR = 2.69). They also found that AKI risk was highest 
for patients who received only taxane-based chemotherapy (which included docetaxel or 
paclitaxel) with a 6-month cumulative incidence of AKI of 2%. The risk was lower in patients who 
received only anthracycline-based chemotherapy (0.7%) (included doxorubicin and epirubicin) 
and only CMF regimen (0.5%) (included cyclophosphamide, methotrexate, and 5-fluorouracil).  
The study by Lahoti et al. was done for patients with acute myelogenous leukemia or 
high‐risk myelodysplastic syndrome who had developed AKI.44 They found that 36% of patients 
had developed AKI (defined as >100% increase in serum creatinine).  
The study by Arellano et al. in patients who had solid tumor metastasized to bones.45 They 
found that 43% of the patients developed renal impairment (defined as at least one eGFR value 
<60 mL/min per 1.73 m2). CKD prevalence (defined as at least 2 eGFR values <60 mL/min per 1.73 
m2, at least 90 days apart) was found to be 35% in this patient population. Pamidronic and 
zoledronic acids are intravenously administered bisphosphonates used to prevent bone 
complications which are also nephrotoxic. They also found that 46% of the CKD patients had 
received these intravenously administered bisphosphonates in the 12 months following their 
confirming eGFR.  
In patients with renal cancer, one of the common treatment options is nephrectomy.  
Huang et al. found that the 3-year probability of not having a CKD (defined as GFR lower than 60 
mL/min per 1·73 m2) was 80% after partial nephrectomy and 35% after radical nephrectomy.46  
Qian et al suggests that 47% of patients developed renal impairment and 27% of patients 
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developed chronic kidney disease, 6 months after multiple myeloma diagnosis.47 54% of patients 
developed renal impairment and 39% of patients developed chronic kidney disease 12 months 
after multiple myeloma diagnosis.  
Salahudeen et al. examined cancer patients admitted to the hospital.48 They found that 
12% of cancer patients had AKI (defined as a two-fold increase in serum creatinine or >50% 
decrease of eGFR). Diabetes, chemotherapy, hyponatremia, antibiotic therapy, intravenous 
contrast and transfer to the ICU were found to be significant predictors of developing AKI in 
hospitalized patients. The median length of hospital stay was 10 days for patients with AKI and 5 
days for patients with AKI. Similarly, the hospital bill was significantly higher in patients with AKI 
($82,835) than patients without AKI ($40,164).  
Another study by Lahoti et al. in hospitalized cancer patients found the incidence rate of 
AKI (defined as a two-fold increase in serum creatinine or >50% decrease of eGFR) in cancer 
patients admitted to the ICU to be 12.6% for AKI where 6% were at risk, 3% with injury and 4% 
with failure.49 They also found that each percent increase in serum creatinine was associated 
with a 0.16% increase in cost. 
STUDIES ASSESSING HEALTHCARE UTILIZATION AND EXPENDITURE 
Qian et al. estimated the healthcare resource use and cost associated with renal 
impairment (RI) in patients with bone metastases from primary tumor using an administrative 
claims database.50 They found that total healthcare cost was $142,267 in  patients with RI vs 
$88,839 in patients without RI. Frequency of outpatient services used in patients with RI was 38.4 
as compared to 26.7 in patients without RI. Frequency of other service (emergency department 
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visits, hospital admissions) used was also greater in the cohort with RI.  
Similar results were found by Bhowmik et al. who looked at healthcare resource use and 
cost for CKD in multiple myeloma patients using an administrative claims database.51 They found 
overall the healthcare resource use (including number of patients with an admission, frequency 
of prescription fills, frequency of office visits and laboratory services) and cost (total, hospital, 
outpatient cost) was significantly higher in patients with CKD than patients without CKD.  
The study by Candiril et al, was done in cancer patients with hematological malignancy 
hospitalized with acute renal failure (ARF).52 They suggested that patients with hematologic 
malignancy and ARF who require renal dialysis had the highest mean total cost ($44,619) compared 
to patients with hematologic malignancy with ARF who do not require renal dialysis ($25,638) and 
patients with hematologic malignancy who have no renal complications or do not require renal 
dialysis ($13,947). Similarly, mean length of stay was highest for patients with hematologic 
malignancy who had ARF and required renal dialysis (17.6 days) compared to patients with 
hematologic malignancy who had ARF and did not require renal dialysis (12.2 days) and patients with 





Chapter 3: GAPS IN LITERATURE 
Six out of ten studies reviewed have been done in a single cancer center or a hospital with 
electronic health records.44-49,52 The results of these studies could not be generalizable to the US 
population. The healthcare utilization studies done by Bhowmik et al. and Qian et al. were done 
with an administrative claims database.50,51 The results of these studies could not be 
generalizable to individuals who are uninsured or individuals with only Medicare or Medicaid. 
The healthcare utilization study done by Lahoti et al. was limited to one cancer center and did 
not document utilization and expenditure well.49 The study by Li et al. was done at a population 
level however it was limited to women above 65 years who were enrolled with Medicare and had 
an early-stage breast cancer diagnosis.43 None of the studies evaluated the socioeconomic and 
clinical risk factors of renal disease in cancer patients which are not limited to a single cancer 
type.  
Another gap is that none of the prior studies assessed health-related quality of life of this 
patient population. Cancer patients with renal disease are vulnerable to adverse effects of cancer 
therapies and this cohort of patients are usually excluded from clinical trials.53 Hence there is a 





Chapter 4: RATIONALE 
Except Li et al., none of the previous studies calculates the propensity to have a renal 
disease in cancer patients at a population level.43 The study by Li et al. was limited to older 
women with breast cancer patients at population level. This would be the first study at 
population level which controlled for sociodemographic, economic and clinical factors. The 
results of this study could be used by clinicians to incorporate care for individuals who have a 
higher propensity to develop renal diseases. There have been studies assessing the expenditures 
and utilization associated with renal disease in cancer patients in the US, however they were 
limited to one cancer center or to patients who were commercially insured.49-51 Our study would 
address this limitation by including patients with all types of insurance and uninsured individuals. 
Our study would also include individuals with all cancer types, thus increasing generalizability. 
There have been no studies which assess the health-related quality of life in cancer patients with 
comorbid renal diseases. Previous studies have shown that patients with renal diseases have 
worse health related quality of life, however this has not been proven in cancer patients. 54,55 Our 
study uses a nationally representative database which is generalizable to the US population to 
assess the health-related quality of life while controlling for sociodemographic, economic and 








Chapter 5: CONCEPTUAL FRAMEWORK 
 We used the Andersen Health Behavioral Model which is widely accepted as a reliable 
tool for the study of health services utilization.56   According to the Andersen model, as shown in 
Figure 2, health service utilization is a sequential and conditional function of three sets of factors: 
predisposing (demographic and social) factors, enabling (economic) factors, and need (clinical) 
factors. Predisposing factors like age, race etc. reflects an individuals’ likelihood to use health 
services. Enabling factors like income, employment and education are the resources that 
facilitate access to services and need factors represent perceived and actual needs of health 
service use, such as self-perceived health status and comorbid chronic conditions. 








Predisposing factors: - 
sex, age, race, marital 
status 
Enabling factors: - 
income, employment, 
education 
Need factors: - Type of 
cancer, number of 
comorbidities, Smoking 
status, Hepatic disease, 
Cardiovascular Disease 
Outcomes: -  
- Economic Outcome - Costs and 
Healthcare utilization  
- Health Outcome - Health 





Chapter 6: SPECIFIC AIMS 
AIM 1: To characterize the sociodemographic, economic and clinical characteristics of cancer 
patients with renal diseases in the US civilian non-institutionalized population 
AIM 2: To compare healthcare costs and utilization of cancer patients with renal diseases and 
cancer patients without renal diseases in the US civilian non-institutionalized population 
AIM 3: To compare health-related quality of life (HRQoL) of cancer patients with renal diseases 






Chapter 7: SPECIFIC AIM 1 
The first aim of our study was to examine the prevalence and predictors of renal disease 
in cancer patients. We studied sociodemographic, economic and clinical characteristics of cancer 
patients with renal diseases in the U.S. civilian non-institutionalized population. We hypothesized 
that certain characteristics would differ significantly between the group of cancer patients with 
renal disease and the group of cancer patients without renal disease. We also hypothesized that 
certain characteristics would be significantly associated with likelihood of having a renal disease 






This study was designed as a retrospective, cross-sectional study using Medical 
Expenditure Panel Survey (MEPS).57 A sample of families and individuals across the United States 
were interviewed for five rounds that covers two years. The data from the interviews was 
collected and compiled into a publicly available dataset. We used data from the interviews 
conducted from January 2009 to December 2018 for our study. We used the Household 
Component (HC) of MEPS which provides data about demographics, health services, charges and 
expenditures, etc. The files were downloaded and merged for this study to improve the sample 
size. 
STUDY SAMPLE 
We identified individuals for our sample using the Medical Conditions files of MEPS. 
Cancer patients from 2016 to 2018 were identified from ICD-10 codes (Table 1 of Appendix) and 
patients were identified from 2009 to 2015 from ICD-9 codes (Table 2 of Appendix).58,59 Renal 
disease diagnosis was identified from the Medical conditions files of 2016 to 2018 using ICD-10 
codes from “N00” to “N39” (Table 3 of Appendix).60 ICD-9 codes from “580”  to “599” (Table 4 of 
Appendix) was used for renal disease diagnosis from the Medical Conditions files of 2009 to 2015.61 
The Medical Condition files are event level files and hence after identifying the medical conditions 
associated with renal disease or cancer, the files were transposed to person-level files in SAS 
using PROC TRANSPOSE. After transposing, each person was identified as a patient with either 
renal disease or cancer or both or none. Figure 3 shows the sample selection process. There were 
241,247 individuals who responded to MEPS from 2009 to 2018 of which 11,441 patients were 
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patients with cancer who were above the age of 18. Out of 11,441 cancer patients, 1,800 
reported a diagnosis of renal disease and 9,641 did not report a diagnosis of renal disease.  
Figure 3: Flow chart of sample size after inclusion and exclusion criteria for cancer patients 














Sociodemographic, economic information including sex, age, race, education, income, 
employment, marital status and census region were obtained from the full year consolidated 
files. Sex was directly used from MEPS which was coded as “Male” and “Female”. Age was a 
continuous variable which was categorized as 18-44 years, 45 – 65 years, and above 65 years 
which was consistent with previous study.75 Race was recoded as a new variable which indicated 
“White”, “Black” and “Other races”. Other races included individuals who identified as American 
MEPS Respondents (2009 – 2018)  
N = 241,247 
Cancer patients ≥ 18 years 
N = 11,441 
Patients with renal 
disease diagnosis 
N = 1,800 
Patients without renal 
disease diagnosis 
N = 9,641 
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Indian, Asian, Native Hawaiian, Pacific Islander and Multiple Races. Marital status was recoded into 
3 categories as “Married”, “Never Married” and “Widowed/Divorced/Separated”. Education was 
recoded to a new variable which indicated “No School or less than High School”, “High School” 
and “College and above”. Census region was used without recoding and labelled as “Northeast”, 
“Midwest”, “South” and “West”. Income was a continuous variable in MEPS and was recoded 
into more meaningful categories as “Low Income”, “Middle Income” and “High Income”. The 
income variable was recoded based on a previous study where low income was defined as 100% 
below the Federal Poverty Line (FPL). In 2021, the FPL for a single person was $12,880 and hence 
low income was defined as an income less than $12,880.62 Middle income was defined as an 
income between 100-400% of FPL, i.e., between $12,880 and $51,520 and high income was 
defined an income above 400% of FPL, i.e., $51,520 and above. Insurance was used without change 
and labelled as “Private”, “Public” and “Uninsured”. Employment was recoded into a new 
variable which represented 2 categories “Employed” and “Unemployed”. Smoking status was 
recoded into a new variable which represented “Smoker” and “Non-smoker”. Perceived health 
status was recoded into a new variable which represented “Excellent”, “Very Good”, “Good”, 
“Fair” and “Poor”. A new categorical variable was created to indicate the number of 
comorbidities a cancer patient would have. Several chronic conditions such as diabetes, asthma, 
arthritis, hypertension, hypercholesterolemia have been causally associated with an increased 
risk of cancer and hence they were used to count the number of comorbidities.63-67 Categorical 
variables which depicted whether a patient had a cardiovascular disease and hepatic disease 
were also used in the analyses. These variables were created from ICD-9 and ICD-10 codes of the 
Medical Condition files.  
31 
 
Apart from the covariates, complex survey variables were also used in selected analyses 
to have unbiased estimates which would account for the survey design and survey non-
response.68 Complex survey variables included a pooled person-level weight, variance estimation 
primary sampling unit and a sampling stratum required for variance estimation. Since this study 
spans over 10 years, the pooled person-level weight was calculated by dividing the person-level 
weight by 10.  
The outcome variable for this aim was created from the medical conditions file as a 
categorical variable which indicated whether the cancer patient had a renal disease diagnosis or 
did not have a renal disease diagnosis.  
 
STATISTICAL ANALYSES 
A preliminary chi-square test was done in SAS using PROC SURVEYFREQ to assess the 
significance of the sociodemographic, economic and clinical characteristics in cancer patients. 
The chi square test was weighted using complex survey variables. The sample was summarized 
using means and frequencies. A multivariable binomial logistic regression model using PROC 
SURVEYLOGISTIC was used to estimate the likelihood of cancer patients to have a renal disease 
and hence characterize the significant factors associated with the presence of renal disease in 
the study sample. The model for multivariate binomial logistic regression was:  
y = β0 + β1Age + β2Sex + β3Race + β4Marital Status + β5Census Region + β6Income + β7Insurance 
Status + β8Employment Status + β9 Smoking Status + β10Health Status + β11Number of 
comorbidities + β12Hepatic disease indicator + β13Cardiovascular disease indicator + ε0 
y = Renal Disease Indicator 
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The probability of having a renal disease was modelled. The variables were considered 
statistically significant based on Type 3 analysis of effects. Results of the logistic regression was 
summarized in Table 3 using odds ratio. The complex sampling design of the MEPS dataset was 
considered by using variables which account for variance estimation strata, person level weights 
and primary sampling unit. A significance level of 0.05 was used. SAS v9.4 was used for statistical 




The inclusion and exclusion criteria resulted in 11,441 cancer patients (weighted 
frequency = 13,858,510). Out of this, 1,800 patients had a renal disease diagnosis (weighted 
frequency = 2,183,534). Table 2 shows the distribution of sociodemographic, economic and 
clinical characteristics of these cancer patients.  
Figure 4: Prevalence of renal disease in cancer patients in non-institutionalized US population 
from 2009 - 2018 
 
 
Table 2: Distribution of sociodemographic, economic and clinical factors in cancer patients in 









without Renal disease 
Freq (%) 
p-value* 
Overall, n (%) 1800 (15.73) 9641 (84.27)  
Agea (years) mean (S.D)   < 0.0001 
 66.20 (14.76) 61.05 (15.85)  
Age groups < 0.001 
18 - 44 years 182 (10.11) 1588 (16.47)  
45 – 64 years 510 (28.33) 3554 (36.86)  
65+ years 1108 (61.56) 4499 (46.67)  
Missing 0 0  
Sex 0.0049 
Male 697 (38.72) 4198 (43.54)  
Female 1103 (61.28) 5443 (56.46)  













White 1506 (83.67) 7828 (81.19)  
Black 212 (11.78) 1282 (13.30)  
Others 82 (4.56) 531 (5.51)  
Missing 0 0  
Marital Status < 0.0001 
Married 951 (52.83) 5584 (57.91)  
Widowed/Divorced/ 
Separated 
678 (37.67) 2845 (29.51)  
Never Married 171 (9.50) 1212 (12.57)  
Missing 0 0  
Education 0.2239 
No School or less than HS 286 (15.89) 1358 (14.09)  
High School 697 (38.72) 3746 (38.85)  
College or above 804 (44.67) 4461 (46.27)  
Missing 13 (0.72) 76 (0.79)  
Census Region 0.0031 
Northeast 270 (15.00) 1737 (18.02)  
Midwest 408 (22.67) 2107 (21.85)  
South 721 (40.06) 3502 (36.32)  
West 400 (22.22) 2284 (23.69)  
Missing 1 (0.06) 11 (0.11)  
Incomea (USD) mean < 0.0001 
 39952.07 46530.11  
Incomeb < 0.0001 
Low 362 (20.11) 1544 (16.01)  
Middle 899 (49.94) 4736 (49.12)  
High 478 (26.56) 2943 (30.53)  
Missing 61 (3.39) 418 (4.34)  
Insurance < 0.0001 
Private 1067 (59.28) 6222 (64.54)  
Public 688 (38.22) 3012 (31.24)  
Uninsured 45 (2.50) 407 (4.22)  
Missing 0 0  
Employment status < 0.0001 
Employed 557 (30.94) 4477 (46.44)  
Unemployed 1243 (69.06) 5097 (52.87)  
Missing 0 67 (0.69)  
Smoking status 0.0028 
Smoker 202 (11.22) 1305 (13.54)  
Non-smoker 1229 (68.28) 6199 (64.30)  
Missing 369 (20.50) 2137 (22.17)  
Health Status < 0.0001 
Excellent 292 (16.22) 2322 (24.08)  
Very Good 491 (27.28) 3054 (31.68)  
Good 528 (29.33) 2604 (27.01)  
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Fair 336 (18.67) 1027 (12.52)  
Poor 153 (8.50) 408 (4.23)  
Missing 0 46 (0.48)  
Number of comorbidities < 0.0001 
0 191 (10.67) 1953 (20.26)  
1 279 (15.50) 2175 (22.56)  
2 454 (25.22) 2352 (24.40)  
3 474 (26.33) 2021 (20.96)  
4+ 402 (22.28) 1140 (11.82)  
Missing 0 0  
Hepatic Disease < 0.0001 
Absent 1762 (97.89) 9555 (99.11)  
Present 38 (2.11) 86 (0.89)  
Missing 0 0  
Cardiovascular Disease < 0.0001 
Absent 533 (29.61) 4493 (46.60)  
Present 1267 (70.39) 5148 (53.40)  
Missing 0 0  
 
P-values are obtained from chi-square test 
a - p-values obtained from Satterthwaite test  
b - Income groups: Low income – less than $12,880; Middle income - between $12,880 and 
$51,520; High income – above $51,520 
HS – High School 
 
 
Almost 2/3rd of the patients with renal disease were older cancer patients. Majority of the 
population identified as whites in both the groups. Nearly half of the population in both the 
groups were married. Majority of the cancer population in both the groups had a high school 
education. Almost half of the cancer population belonged to the middle-income category and 
more than half of the cancer population in both the groups had a private insurance. There were 
more unemployed cancer patients with renal disease than cancer patients without renal disease 
(69.06% vs 52.87%). Unadjusted analyses from the chi-square test and Satterthwaite test shown 
in Table 2 showed that at significance value of 0.05, all the variables differed significantly 
between the two groups except education (p = 0.2239).  
The significant variables were included in the binomial logistic model to calculate the odds 
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ratio. The results from the binomial multivariate logistic regression are shown in Table 3 below. 
The results show that that in the presence of all other variables, only sex, census region, 
employment status, smoking status, health status, number of comorbid diseases, cardiovascular 
and hepatic diseases had significant odds ratio. We found that compared to females, males were 
30% less likely to have renal diseases (p<0.0001). Overall census region significantly predicts 
likelihood of having a renal disease in cancer patients (p=0.0062). The odds of having a renal 
disease were 30% lower in cancer patients living in Northeast than cancer patients living in 
Midwest. We also found that compared to unemployed, cancer patients who were employed 
were almost 30% less likely to have renal diseases (p=0.0010). Smokers were almost 40% less 
likely to have renal disease than non-smokers (p=0.0001). Overall health status significantly 
predicts likelihood of having a renal disease in cancer patients (p=0.0029). Compared to cancer 
patients who reported having a poor health status, cancer patients who reported having an 
excellent health status were almost 40% less likely to have renal diseases. Overall number of 
comorbidities significantly predicts likelihood of having a renal disease in cancer patients 
(p=0.0001). Cancer patients with 4 or more comorbidities were almost 79% more likely to have a 
renal disease than cancer patients with no comorbidities. Cancer patients with hepatic disease 
were almost 3 times more likely to have a renal disease than cancer patients who did not have a 
hepatic disease (p<0.0001). Cancer patients with cardiovascular disease were 27% more likely to 
have a renal disease than cancer patients who did not have a CVD (p=0.00231).  
Table 3: Sociodemographic, Economic and Clinical Factors associated with renal diseases in 
cancer patients in the United States from 2009 - 2018 
Covariates Odds Ratio 95% Confidence Intervals P-value 
Upper limit Lower limit 
Age 0.0536 
18-44 years 0.985 0.749 1.295  
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45-64 years 0.817 0.673 0.991  
65+ years REFERENCE - -  
Sex** < 0.0001 
Male 0.692 0.587 0.817  
Female REFERENCE  -  
Race 0.2420 
Black 0.856 0.712 1.029  
Others 1.025 0.736 1.427  
White REFERENCE - -  
Marital status 0.4083 
Never married 0.973 0.744 1.272  
Widowed/Divorced/Separated 1.098 0.945 1.276  
Married REFERENCE - -  
Census Region** 0.0062 
South 1.001 0.852 1.177  
West 0.836 0.690 1.012  
Northeast 0.712 0.570 0.889  
Midwest REFERENCE - -  
Income 0.6622 
Low 0.905 0.704 1.163  
Middle 0.929 0.785 1.099  
High REFERENCE - -  
Insurance 0.9024 
Uninsured 0.827 0.468 1.459  
Public 0.974 0.821 1.155  
Private  REFERENCE - -  
Employment status** 0.0010 
Employed 0.680 0.560 0.824  
Unemployed REFERENCE - -  
Smoking status** <0.0001 
Smoker  0.634 0.504 0.797  
Non-smoker REFERENCE - -  
Health Status** 0.0029 
Excellent 0.593 0.413 0.851  
Very Good 0.644 0.467 0.889  
Good 0.72 0.527 0.984  
Fair 0.866 0.6 1.25  
Poor REFERENCE - -  
Number of comorbidities**  0.0001 
1 0.978 0.737 1.299  
2 1.276 0.916 1.777  
3 1.437 1.025 2.015  
4+ 1.786 1.254 2.543  
0 REFERENCE - -  
Hepatic Disease** < 0.0001 
Present 2.974 1.727 5.12  
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Absent REFERENCE - -  
Cardiovascular Disease** 0.00231 
Present 1.277 1.034   
Absent REFERENCE -   




Our study examined the characteristics associated with renal disease in cancer patients. 
To our knowledge, this is the first population-based study in cancer patients which was not 
limited to one cancer type. We found that certain characteristics were significantly associated 
with renal disease. One of our findings was that males were less likely to have renal disease than 
females. This could be because pregnancy is a risk factor for renal disease.31 Women are also 
more likely to have a urinary tract infection which is a risk factor for renal disease. 69-70 We found 
that cancer patients who are older (65+ years) are more likely to have a renal disease than cancer 
patients who are between 18 – 44 years and 45 - 64 years, although this finding was not 
statistically significant (p = 0.0536). These were similar to the results reported in the study by 
Lahoti et al. in patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic 
syndrome (OR = 1.8, p = 0.012).44 
Lifestyle risk factors such as smoking have been associated with a risk of CKD and up to 9-
fold increased risk of cancer.71,72 However our study found smoking as a protective factor where 
cancer patients who were smokers were 40% less likely to have a renal disease than cancer 
patients who were non-smokers. As shown in Table 2, almost 20-22% of the data for smoking 
status was missing and hence this association could be biased. This association could be studied 
further in a longitudinal data where causal relationship is established. A meta-analysis in general 
population found that individuals with liver disease were almost twice more likely to have CKD 
(OR = 2.12).73 In our study, cancer patients with liver diseases were almost 3 times more likely to 
have a renal disease (OR = 2.974). Our study also confirmed the association of renal disease and 
CVD in cancer patients (OR = 1.277). This association has been observed in the general population 
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by Foley et al.74 This might be due to shared risk factors such as age between renal disease and 
CVD.   
There are several limitations in this study. Firstly, this study is a cross sectional study and 
hence causality cannot be inferred. The associations that have been found between the 
predictors and outcomes could not be proven true over a longitudinal duration. Secondly, since 
MEPS is a patient reported survey, there may be some self-reporting bias, where individuals tend 
to report inaccurate or false information.75 Thirdly there may also be recall bias where 
participants do not remember previous events or experiences accurately or omit details.75 
Fourthly, the design of data collection is such that one member of the household answers the 
survey for all the other members of the household which may lead to errors.75 We could not 
exclude individuals with a prior renal diagnosis because of missing data for age of diagnosis of 
cancer and renal disease. We have assumed that all the patients who were diagnosed with renal 
disease were treated for it. We did not establish an association of cancer therapies and adjuvant 
drugs to renal disease in cancer patients and this could be a potential hypothesis for further 
research. Finally, the prevalence of individuals diagnosed with renal disease and cancer is 
depicted in the study and could not account for individuals who have cancer and renal disease 
but are undiagnosed.  
Despite the limitations mentioned above, our study still has some implications. Our study 
determines the risk factors associated with renal disease in cancer patients in a nationally 
representative sample. Using a nationally representative sample increases generalizability of our 
results. Our study found that certain factors such as being female, being older, or having a 
comorbid cardiovascular disease or hepatic diseases increases the propensity to develop renal 
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disease in cancer patients. Our study also proves the association of renal disease and cancer 
development. Given the link between renal disease and cancer development, the aim of this 
study highlights the importance of multidisciplinary collaboration between oncologist and 
nephrologist to predict and prevent renal diseases. The results of our study could also inform 
clinicians to incorporate care and heighten monitoring for patients who have more propensity to 
develop renal disease. 
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Chapter 8: SPECIFIC AIM 2 
The second aim of our study was to compare healthcare expenditure and utilization of cancer 
patients with renal diseases and cancer patients without renal diseases in the U.S. civilian non-
institutionalized population. We hypothesized that cancer patients with renal diseases had 




This study was designed as a retrospective, cross-sectional study using Medical 
Expenditure Panel Survey (MEPS).57 A sample of families and individuals across the United States 
were interviewed for five rounds that covers two years. The data from the interviews was 
collected and compiled into a publicly available dataset. We used data from the interviews 
conducted from January 2009 to December 2018 for our study. We used the Household 
Component (HC) of MEPS which provides data about demographics, health services, charges and 
expenditures, etc. The files were downloaded and merged for this study to improve the sample 
size. 
STUDY SAMPLE 
We identified individuals for our sample using the Medical Conditions files of MEPS. 
Cancer patients from 2016 to 2018 were identified from ICD-10 codes (Table 1 of Appendix) and 
patients were identified from 2009 to 2015 from ICD-9 codes (Table 2 of Appendix).58,59 Renal 
disease diagnosis was identified from the Medical conditions files of 2016 to 2018 using ICD-10 
codes from “N00” to “N39” (Table 3 of Appendix).60 ICD-9 codes from “580”  to “599” (Table 4 of 
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Appendix) was used for renal disease diagnosis from the Medical Conditions files of 2009 to 2015.61 
The Medical Condition files are event level files and hence after identifying the medical conditions 
associated with renal disease or cancer, the files were transposed to person-level files in SAS 
using PROC TRANSPOSE. After transposing, each person was identified as a patient with either 
renal disease or cancer or both or none.  There were 241,247 individuals who responded to MEPS 
from 2009 to 2018 of which 11,441 were patients with cancer who were above the age of 18. 
Out of 11,441 cancer patients, 1,800 reported a diagnosis of renal disease (“Renal disease group”) 
and 9,641 did not report renal disease diagnosis (“Control group”). To reduce selection bias, the 
“Renal disease” group was matched in a 1:1 ratio with the Control group using propensity score 
matching (PSM). Propensity score matching is a 2-step process where the first step is to calculate 
the probability of a cancer patient being diagnosed with renal disease. A propensity score was 
calculated using multiple logistic regression with renal disease indicator, sex, age, region, income, 
race and marital status as matching variables, where income and age were used as continuous 
variables. In the second step the Renal disease group and the Control group were matched using 
a greedy matching technique with replacement. The quality of match was assessed using 
standardized differences, where a standardized difference of less than 0.1 was considered a good 
match. Variance ratio, the ratio of treatment variance and control variance was also used to 
compare the quality of match. A ratio closer to 1 was considered a good match. 
VARIABLES 
Sociodemographic, economic information including sex, age, race, education, income, 
employment, marital status and census region were obtained from the full year consolidated 
files. Sex was directly used from MEPS which was coded as “Male” and “Female”. Age was a 
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continuous variable which was categorized as 18-44 years, 45 – 65 years, and above 65 years 
which was consistent with previous study.75 Race was recoded as a new variable which indicated 
“White”, “Black” and “Other races”. Other races included individuals who identified as American 
Indian, Asian, Native Hawaiian, Pacific Islander and Multiple Races. Marital status was recoded into 
3 categories as “Married”, “Never Married” and “Widowed/Divorced/Separated”. Education was 
recoded to a new variable which indicated “No School or less than High School”, “High School” 
and “College and above”. Census region was used without recoding and labelled as “Northeast”, 
“Midwest”, “South” and “West”. Income was a continuous variable in MEPS and was recoded 
into more meaningful categories as “Low Income”, “Middle Income” and “High Income”. The 
income variable was recoded based on a previous study where low income was defined as 100% 
below the Federal Poverty Line (FPL). In 2021, the FPL for a single person was $12,880 and hence 
low income was defined as an income less than $12,880.62 Middle income was defined as an 
income between 100-400% of FPL, i.e., between $12,880 and $51,520 and high income was 
defined an income above 400% of FPL, i.e., $51,520 and above. Insurance was used without change 
and labelled as “Private”, “Public” and “Uninsured”. Employment was recoded into a new 
variable which represented 2 categories “Employed” and “Unemployed”. Smoking status was 
recoded into a new variable which represented “Smoker” and “Non-smoker”. Perceived health 
status was recoded into a new variable which represented “Excellent”, “Very Good”, “Good”, 
“Fair” and “Poor”. A new categorical variable was created to indicate the number of 
comorbidities a cancer patient would have. Several chronic conditions such as diabetes, asthma, 
arthritis, hypertension, hypercholesterolemia have been causally associated with an increased 
risk of cancer and hence they were used to count the number of comorbidities.63-67 Categorical 
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variables which depicted whether a patient had a cardiovascular disease and hepatic disease 
were also used in the analyses. These variables were created from ICD-9 and ICD-10 codes of the 
Medical Condition files. A categorical variable was created which indicated whether the cancer 
patient had a renal disease diagnosis or did not have a renal disease diagnosis was used as the main 
independent variable.  
The outcome variables included healthcare utilization variables and cost variables. The 
utilization variable included the number of office-based visits to the physician and number of 
prescribed medicines which included refills. The healthcare expenditure variables included out-
of-pocket cost associated with the office-based visits to the physician, amount paid for an office-
based visit to the physician from all the sources of payments, out-of-pocket cost associated with 
prescribed medicines including refills and amount paid for prescribed medicines including refills 
from all sources of payments. We also included total out of pocket expenditure which was 
calculated as a sum of out-of-pocket cost associated with inpatient visits, outpatient visits, 
emergency visits, office-based visits to a physician, and out-of-pocket associated with prescribed 
medicines (including refills). Total expenditure from all sources of payment was calculated as a sum 
of expenditure associated with inpatient visits, outpatient visits, emergency visits, office-based 
visits to a physician, and expenditure associated with prescribed medicines (including refills). All 
sources of payment included payments from out of pocket, Medicare, Medicaid, private 
insurance, Veteran’s administration, TRICARE, other federal sources, other state and local 
sources, workers’ compensation, other private, other public, and other unclassified sources. 
STATISTICAL ANALYSES 
The unadjusted mean expenditure for both groups were compared using t-tests. 
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Statistical differences for count outcomes between cancer patients with renal disease and 
without renal disease were analyzed using the Wilcoxon Rank Sum Test. Due to skewed data, 
traditional ordinary least squares (OLS) was not used for modelling the cost outcome. Even 
though the log-transformed OLS would account for the skewed data, the interpretation of 
estimates would be difficult. Therefore, we used a generalized linear model using the log link 
function to model cost outcomes. We used the traditional Poisson regression for modelling the 
count outcomes and assumed that the means and variances are equal. The model was built using 
PROC GLM as following: 
y = β0 + β1Age + β2Sex + β3Race + β4Marital Status + β5Census Region + β6Income + β7Insurance 
Status + β8Employment Status + β9Smoking Status + β10Health Status + β11Number of 
comorbidities + β12Renal Disease Indicator + β13Hepatic disease indicator + β14Cardiovascular 
disease indicator + ε0 
y = # of office-based visits / # of prescribed medicines including refills / out-of-pocket cost 
associated with office-based visits / out-of-pocket cost associated with prescribed medicines 
(including refills) / out-of-pocket cost associated with total medical costs / amount paid by all 
sources of payment associated with office-based visits / amount paid by all sources of payment 
associated with prescribed medicines (including refills) / amount paid by all sources of payment 
associated with total medical costs 
A significance level of 0.05 was used and SAS v9.4 was used for statistical analyses. MS Excel was 





There were 1,736 patients in the treatment group (patients with renal disease) and 9,221 
patients in the control group (patients without renal disease) before matching. The sample 
characteristics before matching and after matching are compared in Table 6 and the distribution 
of propensity score before and after matching is shown below in Figure 5 and 6.  Before matching, 
the mean age for renal disease group was 66.20 years and 61.05 years for control group. The 
renal disease group had a higher proportion of individuals who identified as males (44% vs 39%), 
white (84% vs 81%), widowed/divorced/separated (38% vs 30%) and living in South (40% vs 36%) 
than control group. The mean income was lower in the renal disease group than the control group 
($39,998 vs $46,610). After matching, there were 1,736 patients in the treatment group and 
1,736 patients in the control group. The magnitude of the difference between the treatment and 
control group decreased after matching. The mean and standard deviation of the propensity 
scores of the two groups as shown in Table 4 were equal after matching indicating less variance 
and more balance between the two groups. As shown in Table 5, the absolute value of 
standardized difference of propensity scores and matching variables was closer to 0 after 
matching indicating less variance between the two groups. After matching, the ratio of variance 
of treatment group to control group (variance ratio) was closer to 1 indicating equal variance was 
achieved in both the groups after matching. After matching, the mean age of renal disease group 
was 66.60 years and 66.62 years for control group. The renal disease group had an almost equal 
proportion of individuals who identified as females (61% vs 61%), white (84% vs 84%), married 
(52% vs 53%) and living in South (40% vs 39%) than control group. The mean income was also 
almost equal ($40,039 vs $39,623) in both the groups.  
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Table 4: Distribution of propensity scores of both the groups before and after matching 
 Treated (Renal = YES) Control (Renal = NO) 
 Before Matching After Matching Before Matching After Matching 
Sample size 1736 1736 9221 1736 
Mean 0.1774 0.1774 0.1549 0.1774 
Standard Deviation 0.0544 0.0544 0.0553 0.0544 
Minimum 0.0497 0.0497 0.0307 0.0495 
Maximum 0.3483 0.3483 0.3627 0.3627 
 
Table 5: Metrics to compare quality of match 








Propensity Score Before Matching 0.18 0.42 0.43147 0.7936 
  After Matching -0.00 
 
-0.00007 0.9997 
Age Before Matching 5.11 15.13 0.33772 0.8667 
  After Matching -0.02 
 
-0.00141 1.0939 
Income Before Matching -6578.16 39711.69 -0.16565 0.6772 
  After Matching 416.66 
 
0.01049 1.0677 
Sex Before Matching 0.05 0.49 0.10690 0.9648 




Figure 5: Distribution of propensity scores of cancer patients with renal disease and without 






Figure 6: Distribution of propensity scores of cancer patients with renal disease and without 
renal diseases after matching  
 
Table 6: Sample characteristics of cancer patients with renal disease and without renal 
disease before and after matching 
Variables Before Matching After Matching 
RENAL DISEASE PRESENT ABSENT PRESENT ABSENT 
Age (mean, SD) 
 66.20 (14.76) 61.05 (15.85) 66.60 (14.56) 66.62 (13.94) 
Sex 
Male 697 (43.56) 4200 (38.72) 679 (39.11) 674 (38.82) 
Female 5441 (56.44) 1103 (61.28) 1057 (60.89) 1062 (61.18) 
Race 
White 1506 (83.67) 7828 (81.19) 1453 (83.70) 1466 (84.45) 
Black 212 (11.78) 1282 (13.30) 203 (11.69) 199 (11.46) 
Others 82 (4.55) 531 (5.52) 80 (4.61) 71 (4.09) 










Married 951 (52.83) 5584 (57.92) 911 (52.48) 928 (53.46) 
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Widowed/Divorced/Separated 678 (37.67) 2845 (29.51) 661 (38.08) 655 (37.73) 
Never Married 171 (9.50) 1212 (12.57) 164 (9.45) 153 (8.81) 
Region 
Northeast 269 (14.94) 1740 (18.05) 259 (14.92) 289 (16.65) 
Midwest 407 (22.61) 2109 (21.88) 400 (23.04) 393 (22.64) 
South 721 (40.06) 3506 (36.37) 690 (39.75) 676 (38.94) 
West 399 (22.17) 2284 (23.69) 387 (22.29) 378 (21.77) 
 
UNADJUSTED RESOURCE UTILIZATION AND COSTS  
The sample included 1,736 patients in each group of patients with renal disease and 
without renal disease. As shown in Table 7, respondents with renal disease had higher unadjusted 
mean out-of-pocket cost associated with office-based provider visits ($507.02 vs $464.87, 
p=0.3963), prescribed medicines (including refills) ($1203.21 vs $867.28, p<0.0001) and total 
medical costs ($2041.37 vs $1695.56, p=0.0155) compared to patients without renal disease. 
Unadjusted mean cost from all sources of payment associated with office-based provider visits 
($7069.39 vs $5165.08, p<0.0001), prescribed medicines (including refills) ($9554.65 vs 
$6007.22, p<0.0001) and total medical costs ($33185.46 vs $21133.39, p<0.0001) compared to 
patients without renal disease. Except for out-of-pocket costs associated with office-based 
provider visits (p=0.3963), cancer patients with renal disease had a significantly higher mean 
costs than cancer patients without renal disease. The results for unadjusted utilization measures 
for cancer patients are shown in Table 8. The results show a higher median office-based visits to 
provider (17 vs 12, p<0.0001) and higher median prescriptions filled (including refills) (53 vs 31, 
p<0.0001) for cancer patients with renal disease than cancer patients without renal disease.  
 
Table 7: Unadjusted mean cost estimates for cancer patients with renal disease and without renal disease in propensity matched 
groups from MEPS (2009 – 2018) 
Expenditure measure ($) Cancer Patients with renal disease Patients without renal disease P -value  
Mean ($) SD 95% CI Mean ($) SD 95% CI   
Office-based 
visits 
Out-of- pocket 507.02 1153.04 452.75 -561.30 
 
464.87 1718.52 383.99 – 545.78 0.3963  
All sources of 
payment** 
7069.39 11909.30 6508.78 – 
7630.00 
 





Out-of- pocket** 1203.21 2431.66 1088.74 -
1317.68 
867.28 2535.92 747.91- 986.66 <0.0001  
All sources of 
payment** 
9554.65 21788.23 8529.00 – 
10580.30 





Out-of- pocket** 2041.37 3234.82 1889.10 -
2193.65 
 
1695.56 4994.07 1460.47 – 
1930.65 
0.0155  
All sources of 
payment** 
33185.46 50679.29 30799.81 – 
35571.11 
 








Table 8: Unadjusted utilization estimates for cancer patients with renal disease and without 









Present 17.00 0.00 – 
354.00 
26.56 29.43 25.18 – 
27.95 
< 0.0001 
Absent 12.00 0.00 – 
326.00 






Present 53.00 0.00 – 
836.00 
85.45 100.72 80.71 – 
90.19 
< 0.0001 
Absent 31.00 0.00 – 
720.00 
55.01 72.11 51.62 – 
58.40 
Abbreviation used: SD = Standard deviation; CI = Confidence interval; p-value obtained from 
Wilcoxon signed rank sum test  
ADJUSTED RESOURCE UTILIZATION AND COSTS  
The sample for adjusted analyses included 1,385 cancer patients with renal disease and 
1,342 cancer patients without renal disease. The results of the generalized linear model, after 
including only non-zero costs in matched groups and adjusting for covariates are shown in Table 
9. Similar to unadjusted results, individuals with renal disease had higher costs associated with 
office-based provider visits, prescribed medicines (including refills) and total medical costs 
compared to patients without renal disease. As shown in Table 10, respondents with renal 
disease had higher adjusted mean out-of-pocket cost associated with office-based provider visits 
($711.79 vs $670.70, p<0.0001), prescribed medicines (including refills) ($1370.24 vs $1022.66, 
p<0.0001) and total medical costs ($2274.67 vs $1907.74, p<0.0001) compared to patients 
without renal disease. Adjusted mean cost from all sources of payment associated with office-
based provider visits ($7881.35 vs $5683.24, p<0.0001), prescribed medicines (including refills) 
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($11068.02 vs $6764.57, p<0.0001) and total medical costs ($37283.40 vs $22402.58, p<0.0001) 
compared to patients without renal disease. The results for adjusted utilization measures for 
cancer patients are shown in Table 9. The results show a higher mean office-based visits to 
provider (29.60 vs 19.94, p<0.0001) and higher mean prescriptions filled (including refills) (96.75 
vs 63.32, p< 0.0001) for cancer patients with renal disease than cancer patients without renal 
disease. Median office-based visits to provider was higher for cancer patients with renal disease 
than cancer patients without renal disease (30.50 vs 20.61); this difference represents a 50% 
increase (p < 0.0001). Similarly, median prescriptions filled including refill was increased by 
almost 57% for cancer patients with renal disease than cancer patients without renal disease. 
Similar to unadjusted results, we see a patten of higher mean and median visits to office-based 
provider and prescription fills for patients with renal disease compared to patients without renal 
disease.  
Table 9: Adjusted utilization estimates for cancer patients with renal disease and without 









Present 30.50 7.89 – 77.12 29.60 10.38 29.05 – 
30.15 
< 0.0001 






Present 88.83 15.96 – 
412.25 
96.75 56.76 93.76 – 
99.75 
< 0.0001 
Absent 56.74 12.68 – 
198.41 
63.32 38.40 61.27 – 
65.38 




Figure 7: Adjusted number of prescriptions filled including refills for cancer patients with renal 
disease and without renal disease in propensity matched groups from MEPS (2009 – 2018) 
  
 
 Figure 8: Adjusted number of office-based visits to a physician for cancer patients with renal 




Table 10: Adjusted mean cost estimates for cancer patients with renal disease and without renal disease in propensity matched 
groups from MEPS (2009 – 2018) 
Expenditure measure ($) Patients with renal disease Patients without renal disease P-value 
Mean ($) SD 95% CI Mean ($) SD 95% CI  
Office-based 
visits 
Out-of- pocket 711.79 204.83 700.98 – 722.60  670.70 184.07 660.85 – 680.56 <0.0001 
All sources of 
payment 
7881.35 2728.287 7737.38 – 
8025.32 





Out-of- pocket 1370.24 645.57 1336.17 – 
1404.30 
1022.66 506.92 995.52 – 
1049.81 
<0.0001 
All sources of 
payment 
11068.02 7766.29 10658.21 – 
11477.84 





Out-of- pocket 2274.67 720.16 2236.67 – 
2312.67 
1907.74 608.18 1875.17 – 
1940.31 
<0.0001 
All sources of 
payment 
37283.40 17482.95 36360.85 – 
38205.95 
22402.58 10642.39 21832.67- 
22972.48 
<0.0001 




The major finding of this aim was that mean unadjusted costs and utilization were higher for 
cancer patients with renal disease than cancer patients without renal disease. The sample used 
in this aim were MEPS respondents who were diagnosed with cancer and above the age of 18. 
Previous studies have shown that kidney damage represented by an increase in serum creatinine 
level has been correlated with increased hospital cost in cancer patients admitted to the ICU.49 
Our study showed similar results, kidney damage in cancer patients was associated with higher 
mean out-of-pocket cost for office-based visits ($41), prescribed medicines ($348) and total 
medical cost ($366.93). Apart from out-of-pocket costs, kidney damage was also associated with 
higher costs from all sources of payment for office-based visits ($2,188), prescribed medicines 
($4,303) and total medical costs ($14,881). Similar results were found by Bhowmik et al. in 
patients with multiple myeloma using claims database.51 They found that patients with CKD had 
higher frequency of physician office visits (1.2 vs 0.5), prescription fills (74.6 vs 57.9) than patients 
without CKD. A study by Qian et al. had similar results in patients with bone metastases from 
solid tumor.50 They found that patients with renal impairment had higher physician’s visits (22.9 
vs 18.8), outpatient pharmacy visits (49.2 vs 40.8) and outpatient pharmacy costs ($10,315 vs 
$7,718).  
 There were many limitations for this study. Firstly, to account for the shape of the cost 
and utilization outcomes, we used generalized linear model and Poisson regression model. These 
models could not account for complex sampling weights which are used to produce estimates of 
nationally representative samples. Hence the results of this aim are generalizable only to the 
participants of MEPS and not the US population. Secondly, we assumed that the mean and 
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variances of the utilization variables are equal. Hence, we could not control for overdispersion in 
the Poisson regression. Thirdly, we did a propensity score matching to account for selection bias 
and confounding; however, differences between the cohorts might still exist for unobservable 
characteristics (e.g., stages of cancer, patient preferences). Indirect costs such as loss of 
productivity for the patient or the caregiver was not accounted for and thus the economic burden 
estimated might be underestimated.  
Despite the limitations mentioned above, our study still has some implications. This study 
was the first in cancer patients which was not limited to one cancer type. Unlike the previous 
studies by Bhowmik et al. and Qian et al., the expenditure was accounted for individuals with 
public and private insurance as well as uninsured.50,51 Our study estimates the mean expenditure 
for cancer patients with renal disease. This could be used by payers to estimate savings that can 
potentially accrue if care and preventive measures are incorporated in cancer patients who have 
a propensity to develop renal disease. 
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CHAPTER 9: SPECIFIC AIM 3 
The third aim of our study was to compare health-related quality of life (HRQoL) of cancer 
patients with renal diseases and cancer patients without renal diseases in the U.S. civilian non-
institutionalized population. We hypothesized that the cancer patients with renal disease will 
have lower mean PCS and MCS scores than cancer patients without renal disease. A lower score 
indicates worse HRQoL.    
9.1 METHODS 
STUDY DESIGN 
This study was designed as a retrospective, cross-sectional study using Medical 
Expenditure Panel Survey (MEPS).57 A sample of families and individuals across the United States 
were interviewed for five rounds that covers two years. The data from the interviews was 
collected and compiled into a publicly available dataset. We used data from the interviews 
conducted from January 2009 to December 2018 for our study. We used the Household 
Component (HC) of MEPS which provides data about demographics, health services, charges and 
expenditures, etc. The files were downloaded and merged for this study to improve the sample 
size. 
STUDY SAMPLE 
We identified individuals for our sample using the Medical Conditions files of MEPS. 
Cancer patients from 2016 to 2018 were identified from ICD-10 codes (Table 1 of Appendix) and 
patients were identified from 2009 to 2015 from ICD-9 codes (Table 2 of Appendix).58,59 Renal 
disease diagnosis was identified from the Medical conditions files of 2016 to 2018 using ICD-10 
codes from “N00” to “N39” (Table 3 of Appendix).60 ICD-9 codes from “580”  to “599” (Table 4 of 
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Appendix) was used for renal disease diagnosis from the Medical Conditions files of 2009 to 2015.61 
The Medical Condition files are event level files and hence after identifying the medical conditions 
associated with renal disease or cancer, the files were transposed to person-level files in SAS 
using PROC TRANSPOSE. After transposing, each person was identified as a patient with either 
renal disease or cancer or both or none. Figure 3 shows the sample selection process. There were 
241,247 individuals who responded to MEPS from 2009 to 2018 of which 11,441 patients were 
patients with cancer who were above the age of 18. Out of 11,441 cancer patients, 1,800 
reported a diagnosis of renal disease and 9,641 did not report a diagnosis of renal disease.  
VARIABLES 
Sociodemographic, economic information including sex, age, race, education, income, 
employment, marital status and census region were obtained from the full year consolidated 
files. Sex was directly used from MEPS which was coded as “Male” and “Female”. Age was a 
continuous variable which was categorized as 18-44 years, 45 – 65 years, and above 65 years 
which was consistent with previous study.75 Race was recoded as a new variable which indicated 
“White”, “Black” and “Other races”. Other races included individuals who identified as American 
Indian, Asian, Native Hawaiian, Pacific Islander and Multiple Races. Marital status was recoded into 
3 categories as “Married”, “Never Married” and “Widowed/Divorced/Separated”. Education was 
recoded to a new variable which indicated “No School or less than High School”, “High School” 
and “College and above”. Census region was used without recoding and labelled as “Northeast”, 
“Midwest”, “South” and “West”. Income was a continuous variable in MEPS and was recoded 
into more meaningful categories as “Low Income”, “Middle Income” and “High Income”. The 
income variable was recoded based on a previous study where low income was defined as 100% 
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below the Federal Poverty Line (FPL). In 2021, the FPL for a single person was $12,880 and hence 
low income was defined as an income less than $12,880.62 Middle income was defined as an 
income between 100-400% of FPL, i.e., between $12,880 and $51,520 and high income was 
defined an income above 400% of FPL, i.e., $51,520 and above. Insurance was used without change 
and labelled as “Private”, “Public” and “Uninsured”. Employment was recoded into a new 
variable which represented 2 categories “Employed” and “Unemployed”. Smoking status was 
recoded into a new variable which represented “Smoker” and “Non-smoker”. Perceived health 
status was recoded into a new variable which represented “Excellent”, “Very Good”, “Good”, 
“Fair” and “Poor”. A new categorical variable was created to indicate the number of 
comorbidities a cancer patient would have. Several chronic conditions such as diabetes, asthma, 
arthritis, hypertension, hypercholesterolemia have been causally associated with an increased 
risk of cancer and hence they were used to count the number of comorbidities.63-67 Categorical 
variables which depicted whether a patient had a cardiovascular disease and hepatic disease 
were also used in the analyses. These variables were created from ICD-9 and ICD-10 codes of the 
Medical Condition files. A categorical variable was created which indicated whether the cancer 
patient had a renal disease diagnosis or did not have a renal disease diagnosis and was used as the 
main independent variable. Apart from the covariates, complex survey variables were also used 
in selected analyses to have unbiased estimates which would account for the survey design and 
survey non-response.68 Complex survey variables included a pooled person-level weight, variance 
estimation primary sampling unit and a sampling stratum required for variance estimation. Since 
this study spans over 10 years, the pooled person-level weight was calculated by dividing the 
person-level weight by 10.   
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Health related quality of life (HRQoL) is measured in MEPS using Short Form Health 
Survey-12 version two (SF-12v2) measured in rounds 2 and 4 of a panel. The SF-12v2 measures the 
following eight concepts: physical functioning, role limitations resulting from physical health 
problems, bodily pain, general health, vitality (energy/fatigue), social functioning, role limitation 
resulting from emotional problems, and mental health with 12 questions including “How often 
physical health or emotional problems interfered with social activities”, “Whether they 
accomplished less  than they would like at work or other regular activity as a result of their 
physical health”.76 Responses to these questions are combined to form two summary scores: 
Physical Component Summary (PCS) and Mental Component Summary (MCS). PCS is presented 
as a continuous variable which ranges from 4.48 to 70.51 and MCS is presented as a continuous 
variable which ranges from 3.71 to 75.6. A higher score is indicative of a better HRQoL. The 
reliability of SF-12 instrument was high (Cronbach’s alpha of 0.89 for PCS and 0.88 for MCS) in 
the cancer patients in US.77 PCS and MCS are the patient reported outcomes which were the 
dependent variables in this study. PCS and MCS scores were measured in rounds 2 and 4 of the survey 
and hence each individual had 2 scores of PCS and MCS scores. Hence average PCS and average MCS score 
were used as the outcome variables for this aim.   
STATISTICAL ANALYSES 
Test for normality for PCS scores (p < 0.01) and MCS scores (p < 0.01) showed that the 
outcome variables were fairly normally distributed and hence parametric tests were used for 
analyses. Unadjusted analyses were done using SAS procedure PROC SURVEYMEANS. A multiple 
linear regression model was built to determine the mean PCS and MCS in both groups while 
controlling for the independent variables mentioned above. Means of PCS and MCS were 
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compared using PROC SURVEYREG. The difference between the means of 2 groups were tested 
using T-test and SAS procedure PROC SURVEYREG. The model for multivariate linear regression 
was:  
y = β0 + β1Age + β2Sex + β3Race + β4Marital Status + β5Census Region + β6Income + β7Insurance 
Status + β8Employment Status + β9Smoking Status + β10Health Status + β11Number of 
comorbidities + β12Hepatic disease indicator + β13Cardiovascular disease indicator + β13Renal 
disease indicator + ε0 
y = PCS / MCS score 
The complex sampling design of the MEPS dataset was considered by using variables 
which account for variance estimation strata, person level weights and primary sampling unit. A 
significance level of 0.05 was used. SAS v9.4 was used for statistical analyses and MS Excel was 





Health-related quality of life was calculated using mean PCS and MCS scores in both the 
groups of patients i.e., patients with renal disease and without renal disease. The mean 
unadjusted scores are summarized below in Table 11. Unadjusted analyses showed that patients 
with renal disease had a lower mean PCS (40.57 vs 45.38) and MCS scores (50.39 vs 51.47). We 
did a multivariate analysis by adjusting for sociodemographic, economic and clinical 
characteristics. The results are summarized in Table 12. The results of adjusted analyses were 
similar results to unadjusted analyses. Patients without renal disease had a higher PCS score by 
4.73 points than a patient with renal disease while controlling for other factors. The difference in 
scores was statistically significant (p < 0.0001). On average, patients without renal disease had a 
higher MCS score by 1.06 points than a patient with renal disease while controlling for other 
factors and this difference in scores was also statistically significant (p < 0.0001). 
Table 11: Unadjusted mean HRQoL scores in cancer patients with renal disease and without 







Mean Std. Error of 
Mean 
95% CI for Mean 
PCS 
 
Present 1800 40.57 0.3238 39.93 41.21 
Absent 9641 45.38 0.1796 45.03 45.74 
MCS 
 
Present 1800 50.39 0.3154 49.77 51.01 
Absent 9641 51.47 0.1333 51.21 51.73 
 
Table 12: Adjusted mean HRQoL scores in cancer patients with renal disease and without 







Mean Std. Error of 
Mean 
95% CI for Mean 
PCS Present 1786 40.52 0.2213 40.08 40.95 
Absent 9431 45.25 0.1494 44.96 45.55 
MCS Present 1786 50.31 0.1324 50.05 50.57 






To our knowledge, this analysis is the first to quantify HRQoL of noninstitutionalized 
cancer patients at the national level. It provides vital information to assess the impact of renal 
diseases in cancer patient in the US from a new perspective: quality of life. Previous studies have 
shown that renal diseases have an impact on mortality.78 Our study shows that renal diseases 
also have an impact on quality of life of cancer patients, specifically 4.73 points decrease in PCS 
score and 1.06 points decrease in MC-12S score.  A previous study has suggested that increase in 
HRQoL scores is associated in decrease in healthcare expenditure in cancer patients.84 
A one-point increase in MCS score was associated with 2% decrease in medical expenditures in 
all types of cancer. The association of MCS and medical expenditure was not varied by cancer 
type. There was no significant association between MCS and frequency of healthcare utilization. 
A one-point increase in PCS score was associated with 6% decrease in medical expenditures in 
prostate cancer, 4% decrease in medical expenditures in skin cancer and 1% decrease in medical 
expenditure on other types of cancer.  A one-point increase in PCS score was associated with 1% 
decrease in frequency of healthcare utilization in all types of cancer patients and this association 
did not differ by cancer type.   
A comparison of the PCS and MCS scores for the different populations is shown in the 
Table 13 below. The results were similar to what was reported by Abdel-Kader et al. which 
estimated HRQoL in patients with end stage renal diseases (ESRD) and chronic kidney disease 
(CKD)55. They found that patients with ESRD had a mean PCS score of 36.6 and mean MCS score 
of 44.6. Patients with CKD had mean PCS score of 39.3 and mean MCS score of 44.0. Similar to 
patients with ESRD and CKD in the Abdel-Kader et al study, cancer patients in our study reported 
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worse physical health than mental health status. In our study which included cancer patients, the 
PCS and MCS score was higher than that reported for adults with CKD only or ESRD only in the 
study by Abdel-Kader et al.55 These findings indicate that cancer patients with and without 
comorbid renal diseases report better HRQoL than adults with only CKD or ESRD. These findings 
are similar to the study by Naylor et al. which indicate that patients on CKD have worse outcomes 
than cancer patients.79  
Our study had some limitations. Firstly, this study is a cross sectional study and hence 
causality cannot be inferred. The associations that have been found between the predictors and 
outcomes could not be proven true over a longitudinal duration. Secondly, since MEPS is a patient 
reported survey, there may be some self-reporting bias, where individuals tend to report 
inaccurate or false information.75 



















50.04 45.25 40.52 39.3 36.6 
Mean MCS 
Scores 
51.50 51.37 50.31 44.0 44.6 
 
Thirdly there may also be recall bias where participants do not remember previous events 
or experiences accurately or omit details.75 Fourthly, the design of data collection is such that 
one member of the household answers the survey for all the other members of the household 
which may lead to errors.75 We could not exclude individuals with a prior renal diagnosis because 
of missing data for age of diagnosis of cancer and renal disease. We have assumed that all the 
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patients who were diagnosed with renal disease were treated for it. The study could not establish 
an association of cancer therapies and adjuvant drugs to renal disease in cancer patients. Finally, 
we could not account for disease severity. It is intuitive that individuals with severe disease would 
have worse outcomes. The quality of life could be associated with only cancer and not renal 
disease.  Our study did not assess the HRQoL using disease-specific questionnaire like The Kidney 
Disease Quality of Life survey (KDQOL) which would have given a more responsive and clinically 
useful than generic quality of life scale like SF-12 v2.81 In 2018, the SF-12v2 was replaced by the 
Veteran’s RAND 12-item (VR-12) and was administered to individuals who identified as Veterans 
in Round 1 of the interviews. The stage of cancer and type of cancer could also have some effect 
on the quality of life of cancer patients and we could not control for that in our study.   
Despite these limitations, our study had some strong implications. None of the studies 
have evaluated HRQoL associated with renal diseases in cancer patients. Previous studies have 
shown that incorporating of early palliative care the patient’s increase quality of life.54,82 Thus, 
we encourage clinicians and other stakeholders to integrate early palliative care to relieve 
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Table 1: International Classification of Diseases, Tenth Revision (ICD-10) Codes to identify 
cancer patients 
C00- C14 Malignant neoplasms of lip, oral 
cavity and pharynx 
C73- C75 Malignant neoplasms of thyroid and 
other endocrine glands 
C15- 
C26 




Malignant neoplasms of ill-defined, 
other secondary and unspecified 
sites 
C30- C39 Malignant neoplasms of 
respiratory and intrathoracic 
organs 
C7A Malignant neuroendocrine tumors 
C40- 
C41 
Malignant neoplasms of bone 
and 
articular cartilage 
C7B Secondary neuroendocrine tumors 
C43- 
C44 
Melanoma and other malignant 
neoplasms of skin 
C81- 
C96 
Malignant neoplasms of lymphoid, 
hematopoietic and related tissue 
C45- 
C49 
Malignant neoplasms of 
mesothelial and soft tissue 
D00- 
D09 
In situ neoplasms 
C50-  Malignant neoplasms of breast D10- 
D36 
Benign neoplasms, except benign 
neuroendocrine tumors 
C51- C58 Malignant neoplasms of female 
genital organs 
D37- D48 Neoplasms of uncertain behavior, 





Malignant neoplasms of male 
genital organs 
D3A Benign neuroendocrine tumors 
C64- 
C68 
Malignant neoplasms of urinary 
tract 
D49 Neoplasms of unspecified behavior 
C69- C72 Malignant neoplasms of eye, 











Malignant neoplasms of lip, oral 
cavity and pharynx 
200- 
209 
Malignant neoplasms of lymphatic 
and hematopoietic tissue 
150- 
159 
Malignant neoplasms of digestive 






Malignant neoplasms of 
respiratory and intrathoracic 
230- 
234 






Malignant neoplasms of bone, 
connective tissue, skin and breast 
235- 
238 
Neoplasms of uncertain behavior 
179- 
189 
Malignant neoplasms of 
genitourinary organs 
239 Neoplasms of unspecified nature 
190- 
199 
Malignant neoplasms of other 










Renal tubulo-interstitial diseases N25- 
N29 












Table 4: International Classification of Diseases, Ninth Revision (ICD-9) Codes to identify renal 
diseases 
580-589 Nephritis, Nephrotic Syndrome, 
and Nephrosis 





Table 5: Overview of covariates used in study 
Variable name in study Variable name in MEPS Operationalization 
Age AGEyyX 18 – 44 years, 45 – 64 years, 65+ years 
Sex SEX Male, Female 
Race RACEV1X, RACEX White, Black, Other races 
Marital status MARRY31X Married, Never married, Divorced / 
Widowed / Separated 
Census region REGIONyy Northeast, Midwest, South, West 
Income TTLPyyX Low, Middle, High 
Insurance  INSCOVyy Private, Public, Uninsured 
Education HIDEG, EDUYRYDG No school or less than highschool, 
Highschool, College or above 
Employment status EMPST31 Employed, Unemployed 
Health Status RTHLTH31 Excellent, Very Good, Good, Fair, Poor 
Smoking status ADSMOK42, OFTSMK53 Smoker, Non-smoker 
Number of comorbidities Multiple variables 0, 1, 2, 3, 4+ 
Hepatic Disease ICD10CDX, ICD9CODX Present, Absent 
Cardiovascular Disease ICD10CDX, ICD9CODX Present, Absent 
yy – represents the year example AGE17X for age as of 2017 
 
